These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 18698545

  • 21. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):142-7. PubMed ID: 17991875
    [Abstract] [Full Text] [Related]

  • 22. Modified serum profiles of inflammatory and vasoconstrictive factors in patients with emotional stress-induced acute coronary syndrome during World Cup Soccer 2006.
    Wilbert-Lampen U, Nickel T, Leistner D, Güthlin D, Matis T, Völker C, Sper S, Küchenhoff H, Kääb S, Steinbeck G.
    J Am Coll Cardiol; 2010 Feb 16; 55(7):637-42. PubMed ID: 20170788
    [Abstract] [Full Text] [Related]

  • 23. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial.
    Loughrey BV, McGinty A, Young IS, McCance DR, Powell LA.
    Clin Endocrinol (Oxf); 2013 Dec 16; 79(6):800-6. PubMed ID: 23170936
    [Abstract] [Full Text] [Related]

  • 24. Benefit and tolerability of the coadministration of ezetimibe and atorvastatin in acute coronary syndrome patients.
    Hamdan R, Hajj F, Kadry Z, Kassab R, Salame E, Aboujaoude S, Azar R, Badaoui G.
    J Med Liban; 2011 Dec 16; 59(2):65-9. PubMed ID: 21834489
    [Abstract] [Full Text] [Related]

  • 25. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.
    Arterioscler Thromb Vasc Biol; 2009 Mar 16; 29(3):424-30. PubMed ID: 19122170
    [Abstract] [Full Text] [Related]

  • 26. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
    Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, Yilmaz A, Daniel WG, Garlichs CD.
    Clin Sci (Lond); 2009 Jan 16; 116(1):45-52. PubMed ID: 18459941
    [Abstract] [Full Text] [Related]

  • 27. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.
    Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators.
    Am Heart J; 2008 May 16; 155(5):954-8. PubMed ID: 18440347
    [Abstract] [Full Text] [Related]

  • 28. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
    Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ.
    Am J Cardiol; 2007 Mar 01; 99(5):632-5. PubMed ID: 17317362
    [Abstract] [Full Text] [Related]

  • 29. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
    Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC.
    J Am Coll Cardiol; 2008 Nov 18; 52(21):1693-701. PubMed ID: 19007688
    [Abstract] [Full Text] [Related]

  • 30. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.
    Hartford M, Wiklund O, Mattsson Hultén L, Persson A, Karlsson T, Herlitz J, Caidahl K.
    J Intern Med; 2007 Nov 18; 262(5):526-36. PubMed ID: 17908161
    [Abstract] [Full Text] [Related]

  • 31. Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).
    Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, Ramchandran P, Rane R, Barkate H, Jindal C.
    J Assoc Physicians India; 2013 Feb 18; 61(2):97-101. PubMed ID: 24471247
    [Abstract] [Full Text] [Related]

  • 32. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
    Gómez-Hernández A, Sánchez-Galán E, Ortego M, Martín-Ventura JL, Blanco-Colio LM, Tarín-Vicente N, Jiménez-Nacher JJ, López-Bescos L, Egido J, Tuñón J.
    Am J Cardiol; 2008 Jul 01; 102(1):12-8. PubMed ID: 18572029
    [Abstract] [Full Text] [Related]

  • 33. The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
    Vasilieva E, Kasyanova O, Shpektor A.
    Acute Card Care; 2008 Jul 01; 10(3):181-4. PubMed ID: 18608041
    [Abstract] [Full Text] [Related]

  • 34. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease.
    Yu CM, Zhang Q, Lam L, Lin H, Kong SL, Chan W, Fung JW, Cheng KK, Chan IH, Lee SW, Sanderson JE, Lam CW.
    Heart; 2007 Aug 01; 93(8):933-9. PubMed ID: 17344325
    [Abstract] [Full Text] [Related]

  • 35. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
    Indian Heart J; 2001 Aug 01; 53(2):237. PubMed ID: 11428488
    [No Abstract] [Full Text] [Related]

  • 36. Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions.
    Kubica J, Kozinski M, Krzewina-Kowalska A, Zbikowska-Gotz M, Dymek G, Sukiennik A, Piasecki R, Bogdan M, Grzesk G, Chojnicki M, Dziedziczko A, Sypniewska G.
    Int J Mol Med; 2005 Jul 01; 16(1):173-80. PubMed ID: 15942695
    [Abstract] [Full Text] [Related]

  • 37. Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
    Colivicchi F, Tubaro M, Santini M.
    Int J Cardiol; 2011 Oct 06; 152(1):56-60. PubMed ID: 20674999
    [Abstract] [Full Text] [Related]

  • 38. Effects of short-term anti-inflammatory therapy on endothelial function in patients with non-ST-segment elevation acute coronary syndrome.
    Chyrchel M, Dudek D, Rzeszutko L, Dziewierz A, Chyrchel B, Rakowski T, Dubiel JS.
    Cardiovasc Revasc Med; 2011 Oct 06; 12(1):2-9. PubMed ID: 21241965
    [Abstract] [Full Text] [Related]

  • 39. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
    Barderas MG, Tuñón J, Dardé VM, De la Cuesta F, Jiménez-Nácher JJ, Tarín N, López-Bescós L, Egido J, Vivanco F.
    Proteomics; 2009 Apr 06; 9(7):1982-93. PubMed ID: 19294693
    [Abstract] [Full Text] [Related]

  • 40. Role of amiodarone on the systemic inflammatory response induced by cardiac surgery: proinflammatory actions.
    Karth GD, Buberl A, Nikfardjam M, Meyer B, Wollenek G, Grimm M, Lassnigg A, Brannath W, Hiesmayr M, Heinz G.
    Can J Anaesth; 2007 Apr 06; 54(4):262-8. PubMed ID: 17400977
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.